Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder
NCT06847399 on ClinicalTrials.gov · last registry update 2025-09-22
Recruiting now, toward 105 participants. Due to report 1 December 2027, alongside 38 other tracked readouts that quarter. Primary outcome, as filed: Percent initial weight loss. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.
- Status
- RECRUITING
- Phase
- P2
- Drug
- tirzepatideZepbound, Mounjaro
- Sponsor
- Johns Hopkins University
- Sponsor type
- Other
- Enrollment
- 105
- Started
- 2025-09-17
- Primary completion
- 2027-12-01 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Percent initial weight loss
Conditions studied
Obesity and Overweight · Binge Eating Disorder
Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.